Holen Sie sich die Stockscreener-App
0.5156
27.38%
-0.1944
Handel nachbörslich:
.52
0.00442
+0.86%
Schlusskurs vom Vortag:
$0.71
Offen:
$0.515585
24-Stunden-Volumen:
115
Relative Volume:
0.64
Marktkapitalisierung:
$N/A
Einnahmen:
-
Nettoeinkommen (Verlust:
$-22.01M
KGV:
-0.00604
EPS:
-85.4
Netto-Cashflow:
$-18.31M
1W Leistung:
-27.38%
1M Leistung:
-27.38%
6M Leistung:
-81.55%
1J Leistung:
-88.61%
1-Tages-Spanne:
$0.5156
$0.5156
1-Wochen-Bereich:
$0.5156
$0.5156
52-Wochen-Spanne:
$0.5156
$0.9389
Vaccinex Inc Stock (VCNX) Company Profile
Vergleichen Sie VCNX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VCNX
Vaccinex Inc
|
0.5156 | 0 | 0 | -22.01M | -18.31M | -85.40 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.46 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
598.16 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
467.55 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
663.73 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.97 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Vaccinex Inc Stock (VCNX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-09-23 | Herabstufung | BTIG Research | Buy → Neutral |
| 2018-09-04 | Eingeleitet | Ladenburg Thalmann | Buy |
Vaccinex Inc Aktie (VCNX) Neueste Nachrichten
Vaccinex (NASDAQ:VCNX) Trading 26.3% Higher – Here’s Why - Defense World
Cannabinoid Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - India Shorts
Progressive Supranuclear Palsy Market on Upward Trajectory During the Forecast Period (2025-2034) with Emerging Immunotherapies | DelveInsight - The Malaysian Reserve
Huntington’s Disease Market to Expand Significantly by 2034, States DelveInsight Report | Prilenia Therapeutics, Neurocrine Biosciences, Som Biotech, Annexon Biosciences, Vaccinex, Sage Therapeutics - Barchart.com
Huntington's Disease Market To Expand Significantly By 2034, States Delveinsight Report Prilenia Therapeutics, Neurocrine Biosciences, Som Biotech, Annexon Biosciences, Vaccinex, Sage Therapeutics - Menafn
Best Biotech Penny Stocks Right Now • Updated Daily - Benzinga
Cannabinoid Agonist Clinical Trial Pipeline Appears Robust - GlobeNewswire
Alzheimer’s Therapeutics Market on Upward Trajectory Across - GlobeNewswire
Vaccinex (NASDAQ:VCNX) Shares Down 2.7% – Time to Sell? - Defense World
Alzheimer's Disease Clinical Trials 2025: EMA, PDMA, FDA - openPR.com
Vaccinex (NASDAQ:VCNX) Shares Down 2.4% – Time to Sell? - Defense World
Vaccinex presents promising cancer treatment data at ASCO By Investing.com - Investing.com India
Vaccinex to Report Promising New Clinical Results of Neoadjuvant - GuruFocus
Vaccinex presents promising cancer treatment data at ASCO - Investing.com
Vaccinex, Inc. to Present New Data on Pepinemab's Role in Enhancing Immune Responses in Head and Neck Cancer at ASCO 2025 - Nasdaq
Vaccinex to Report Promising New Clinical Results of - GlobeNewswire
Clinical Trial Success: New Drug Transforms Cold Tumors into Hot Immune Centers in Head and Neck Cancer - Stock Titan
Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting - GlobeNewswire
Vaccinex (NASDAQ:VCNX) Stock Price Down 11.3% – Here’s What Happened - Defense World
AbTherx, Single Cell Technology, and Vaccinex Announce Collaboration to Tackle Challenging Antibody Drug Targets - ACCESS Newswire
Vaccinex (NASDAQ:VCNX) Trading 9.9% Higher – Still a Buy? - Defense World
Vaccinex reports pepinemab boosts immune response in cancer By Investing.com - Investing.com South Africa
Vaccinex (VCNX) Presents New Findings on Pepinemab for Cancer Tr - GuruFocus
Vaccinex to Report Promising New Clinical Data Revealing Pepinem - GuruFocus
Vaccinex to Report Promising New Clinical Data Revealing Pepinemab's Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR) | VCNX Stock News - GuruFocus
Vaccinex to Report Promising New Clinical Data Revealing Pepinemab's Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR) - The Manila Times
Vaccinex reports pepinemab boosts immune response in cancer - Investing.com Australia
Vaccinex, Inc. Announces Promising Data on Pepinemab as Neoadjuvant Immunotherapy in Metastatic Melanoma and Head and Neck Cancer at AACR 2025 - Nasdaq
Vaccinex to Report Promising New Clinical Data Revealing - GlobeNewswire
VACCINEX, INC. SEC 10-K Report - TradingView
Pre-market Movers In Healthcare Sector: CTXR, VCNX, SRNE, ITRM, RWLK… - RTTNews
Osteosarcoma Market Set for Groundbreaking Expansion by 2032, Forecasts DelveInsight | Aurora Biopharma, BioAtla, Iovance Biotherapeutics, Isofol Medical AB, Bristol-Myers Squibb, Cellestia Biotech - The Globe and Mail
Vaccinex Delays Yearly Report Filing - TipRanks
Vaccinex director resigns, no disagreement cited By Investing.com - Investing.com South Africa
Vaccinex director resigns, no disagreement cited - Investing.com India
Stocks in play: Neo Performance Materials Inc. - The Globe and Mail
Finance Watch: Sutro Halves Workforce, Cuts Lead ADC And CEO Moves On - Citeline News & Insights
Vaccinex plans Nasdaq exit as Alzheimer market pressure grows - Yahoo Finance
Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market - GlobeNewswire
Can Vaccinex Survive After Nasdaq Exit? Key Details on Company's Future Strategy - StockTitan
Vaccinex Stock Price, Quotes and Forecasts | OTC:VCNX - Benzinga
Vaccinex (NASDAQ:VCNX) Stock Price Down 3.7% – Time to Sell? - Defense World
Alzheimer's Disease Clinical Trial Pipeline | 110+ Companies Pioneering Breakthroughs in Treatment | - EIN News
RFK Jr. says he's resigned from anti-vaccine nonprofit as he seeks nation's top health official job - AP News
Louisiana forbids public health workers from promoting COVID, flu and mpox shots : ShotsHealth News - NPR
United States shares lower at close of trade; Dow Jones Industrial Average down 0.61% - Investing.com India
Vaccinex to be delisted from Nasdaq over equity shortfall - Investing.com
Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire
SIMM Launches WNY Stock Index - The Bona Venture
Vaccinex Inc (VCNX) Quarterly 10-Q Report - Quartz
75+ Key Companies Charting New Frontiers in Multiple Sclerosis Therapeutic Space | DelveInsight - Yahoo Finance
Finanzdaten der Vaccinex Inc-Aktie (VCNX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.55%
0.38%
Kapitalisierung:
|
Volumen (24h):